An open-label, randomized, single dose, crossover study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of modified release formulations of GSK89075 [remogliflozin etabonate] in healthy volunteers.

Trial Profile

An open-label, randomized, single dose, crossover study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of modified release formulations of GSK89075 [remogliflozin etabonate] in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Remogliflozin etabonate (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Oct 2008 Status changed from active, no longer recruiting to completed.
    • 18 Jan 2008 Status changed from initiated to in progress, in accordance with clinicaltrials.gov.
    • 28 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top